FINNENCE ▪ THE WIRE FILE
THE WIRE · № 81927
News■ Unclear/unknown
Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
CFO appointment at a small-cap radiotherapeutics firm; governance news only.
Small-cap management change, no fundamental shift
CATALYST TO WATCH
Clinical trial or financing updates
MAIN RISK
Microcap, limited liquidity and coverage
FULL DISPATCH
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced the appointment of Matt David, M.D., as Chief Financial Officer. Dr. David will lead the...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
OrbiMed lève 3 milliards de dollars auprès de fonds de capital-investissement mondiaux et asiatiques.2026-10-15 11:30 UTC
OrbiMed lève 3 milliards de dollars auprès de fonds de capital-investissement mondiaux et asiatiques.2026-10-15 11:30 UTC
→CORRELATIONshares Healthcare
OrbiMed Raises $3 Billion Across Global and Asia Private Equity Funds2026-10-15 11:30 UTC
OrbiMed Raises $3 Billion Across Global and Asia Private Equity Funds2026-10-15 11:30 UTC
→CORRELATIONshares Healthcare
Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health2026-10-15 11:30 UTC
Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health2026-10-15 11:30 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3) — Merck Sharp & Dohme LLC2026-10-15 12:00 UTC
New Phase 3 trial: Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3) — Merck Sharp & Dohme LLC2026-10-15 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive Subjects — Onconic Therapeutics Inc.2026-10-15 12:00 UTC
New Phase 3 trial: Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive Subjects — Onconic Therapeutics Inc.2026-10-15 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: A Phase 3 Study of Deutenzalutamide in Patients With High-Risk BCR Prostate Cancer — Hinova Pharmaceuticals Inc.2026-10-15 12:00 UTC
New Phase 3 trial: A Phase 3 Study of Deutenzalutamide in Patients With High-Risk BCR Prostate Cancer — Hinova Pharmaceuticals Inc.2026-10-15 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.